Are injections better than pills for weight loss? It is one of the most common questions asked by people exploring medical options for obesity management in the UK. Injectable GLP-1 receptor agonists such as semaglutide (Wegovy) and liraglutide (Saxenda) have transformed the treatment landscape, yet licensed oral options including orlistat and naltrexone/bupropion (Mysimba) remain clinically relevant for many patients. This article compares how each works, what the clinical evidence shows, their side effect profiles, NHS eligibility criteria, and practical considerations — helping you have an informed conversation with your GP or specialist.

How Weight Loss Injections and Pills Work in the Body

Injectable GLP-1 receptor agonists mimic a gut hormone to suppress appetite and slow gastric emptying, while orlistat blocks fat-digesting enzymes and naltrexone/bupropion acts on hypothalamic and reward pathways to reduce appetite and cravings.

Weight loss medications work through distinct pharmacological mechanisms depending on their formulation. Understanding how each type acts in the body helps clarify why outcomes may differ between individuals.

Injectable GLP-1 receptor agonists — such as semaglutide (Wegovy) and liraglutide (Saxenda) — mimic the glucagon-like peptide-1 hormone naturally released after eating. They work primarily by:

• Suppressing appetite via centres in the brain's hypothalamus

• Slowing gastric emptying, so you feel full for longer

• Increasing glucose-dependent insulin secretion and suppressing glucagon release

Because these injections are administered subcutaneously (under the skin), they bypass first-pass metabolism in the liver, allowing the active compound to reach systemic circulation efficiently. Liraglutide (Saxenda) is administered daily, whilst semaglutide (Wegovy) is administered once weekly, reflecting their different half-lives.

Oral weight loss medications currently licensed in the UK include:

• Orlistat (Alli 60 mg over the counter; Xenical 120 mg on prescription) works entirely differently from GLP-1 receptor agonists. It inhibits pancreatic and gastric lipases — enzymes responsible for breaking down dietary fat — so approximately one-third of ingested fat passes through the gut unabsorbed, reducing overall calorie intake.

• Naltrexone/bupropion (Mysimba) is a licensed oral anti-obesity medicine combining an opioid antagonist with a dopamine and noradrenaline reuptake inhibitor. It acts on hypothalamic pathways to reduce appetite and food cravings, and on the mesolimbic reward system to reduce the reinforcing effects of eating.

It is worth noting that oral semaglutide (Rybelsus) uses the same GLP-1 mechanism as the injectable form but is licensed in the UK only for type 2 diabetes, not for weight management. It is not an approved weight loss treatment in the UK and should not be considered equivalent to Wegovy for obesity. Oral bioavailability of semaglutide is considerably lower than the injectable route even with its absorption enhancer (SNAC), which has implications for dosing and efficacy in its licensed indication.

This fundamental pharmacological difference between delivery methods and between individual agents is central to understanding why clinical outcomes can vary significantly.

Comparing Effectiveness: What the Clinical Evidence Shows

Semaglutide (Wegovy) produces the greatest average weight loss of licensed UK options at approximately 14.9% over 68 weeks, compared with around 5–8% for naltrexone/bupropion and 3–5% for orlistat.

Clinical trial data consistently demonstrates that injectable GLP-1 receptor agonists produce greater average weight loss than currently available licensed oral options in the UK, though individual responses vary considerably.

The STEP 1 trial (New England Journal of Medicine, 2021) found that once-weekly subcutaneous semaglutide 2.4 mg (Wegovy) produced an average body weight reduction of approximately 14.9% over 68 weeks in adults with obesity, compared with 2.4% with placebo. Similarly, liraglutide 3 mg (Saxenda) demonstrated average weight loss of around 8% in the SCALE Obesity and Prediabetes trial.

Among licensed oral options:

• Orlistat — the most widely used oral weight loss medicine in the UK — produces average weight loss of approximately 3–5% of body weight over 12 months when combined with dietary changes, though some individuals achieve greater reductions. Its effectiveness is highly dependent on dietary fat intake; those who do not reduce fat consumption experience significant gastrointestinal side effects without proportionate benefit.

• Naltrexone/bupropion (Mysimba) has demonstrated average weight loss of approximately 5–8% in clinical trials when combined with lifestyle intervention, positioning it between orlistat and injectable GLP-1 receptor agonists in terms of average efficacy.

Note that comparisons with oral semaglutide formulations studied for obesity in research settings are not applicable to UK clinical practice, as no oral semaglutide product is currently licensed for weight management in the UK.

It is important to note that no medication works in isolation. All licensed weight loss treatments are intended as adjuncts to a reduced-calorie diet and increased physical activity. NICE guidance (CG189) emphasises that lifestyle intervention remains the cornerstone of obesity management. Furthermore, weight loss achieved during treatment is often not fully maintained after stopping medication — data from the STEP 4 extension study, for example, demonstrated significant weight regain following discontinuation of semaglutide. Long-term adherence, tolerability, and individual metabolic factors all influence real-world outcomes beyond what clinical trials can fully capture.

Side Effects and Safety Considerations for Each Option

Injectable GLP-1 receptor agonists most commonly cause nausea and gastrointestinal symptoms; orlistat causes oily stools and faecal urgency; naltrexone/bupropion is contraindicated in seizure disorders, uncontrolled hypertension, and those taking opioids.

Not sure if this is normal? Chat with one of our pharmacists →

Both injectable and oral weight loss medications carry distinct side effect profiles, and understanding these is essential for informed decision-making alongside a healthcare professional.

Injectable GLP-1 receptor agonists (semaglutide, liraglutide) most commonly cause gastrointestinal symptoms, particularly during dose escalation:

• Nausea, vomiting, and diarrhoea (most frequent, especially in early weeks)

• Constipation and abdominal discomfort

• Rare but serious risks include pancreatitis and gallbladder disease

• Based on animal studies, a theoretical concern exists regarding thyroid C-cell tumours, though this has not been confirmed in humans; these medicines are contraindicated in those with a personal or family history of medullary thyroid carcinoma or MEN2

• In people with type 2 diabetes, a caution regarding worsening of diabetic retinopathy has been noted with semaglutide; this should be discussed with a specialist

• When used alongside insulin or sulfonylureas, there is an increased risk of hypoglycaemia; dose adjustments of those medicines may be required

Patients should contact their GP promptly if they experience severe or persistent abdominal pain, as this may indicate pancreatitis.

Orlistat produces predominantly gastrointestinal side effects directly related to its mechanism — unabsorbed fat in the bowel causes:

Experiencing these side effects? Our pharmacists can help you navigate them →

• Oily or fatty stools and faecal urgency

• Flatulence with oily discharge

• Potential malabsorption of fat-soluble vitamins (A, D, E, K); a multivitamin supplement is recommended, taken at bedtime or at least 2 hours before or after an orlistat dose

• Orlistat should be skipped if a meal is fat-free or a meal is missed

Important interactions with orlistat include:

• Ciclosporin: avoid concomitant use (reduced ciclosporin absorption)

• Warfarin and other anticoagulants: monitor INR closely, as orlistat may affect vitamin K absorption

• Levothyroxine: separate doses by at least 4 hours and monitor thyroid function

• Antiepileptics (e.g., valproate, lamotrigine) and some antiretrovirals: reduced absorption possible; seek specialist advice

Rare but serious risks with orlistat include severe hepatic injury and oxalate nephropathy; patients should seek prompt medical review if they develop jaundice, dark urine, or significant flank pain.

Naltrexone/bupropion (Mysimba) is contraindicated in uncontrolled hypertension, seizure disorders, eating disorders, and in those taking opioid medicines or undergoing opioid withdrawal. It carries a risk of raised blood pressure and heart rate, and should be used with caution in people with cardiovascular disease.

Pregnancy and breastfeeding: All three treatments are contraindicated in pregnancy. Women of childbearing age should use effective contraception. Semaglutide should be stopped at least 2 months before a planned pregnancy due to its long half-life. Breastfeeding is not recommended during treatment with GLP-1 receptor agonists or naltrexone/bupropion; orlistat should also be avoided during breastfeeding.

Any new or worsening symptoms during treatment warrant prompt medical review. Patients and carers are encouraged to report suspected side effects via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Who Is Eligible for Weight Loss Treatment on the NHS

Orlistat is available on the NHS at BMI ≥30 kg/m²; Wegovy requires BMI ≥35 kg/m² with a comorbidity and referral to a specialist weight management service under NICE TA875.

Access to weight loss medication on the NHS is governed by NICE guidance and is not universally available — eligibility depends on clinical criteria, comorbidities, and the specific treatment being considered.

Orlistat (Xenical) is the most accessible NHS-funded option. According to NICE guidance (CG189), orlistat may be prescribed when:

• BMI is ≥30 kg/m², or ≥28 kg/m² with an obesity-related condition (e.g., type 2 diabetes, hypertension)

• The individual has made a genuine attempt at lifestyle modification

• It is prescribed as part of an overall weight management plan

Orlistat should be stopped after 12 weeks if the person has not lost at least 5% of their initial body weight at the full therapeutic dose — this is a standard stop-rule to avoid continued treatment without meaningful benefit.

Semaglutide (Wegovy) received NICE approval in 2023 (TA875) for use within specialist weight management services. Eligibility criteria include:

• BMI ≥35 kg/m² with at least one weight-related comorbidity, or BMI 30–34.9 kg/m² in certain high-risk groups

• Ethnicity-adjusted BMI thresholds apply: for people from Black African, African-Caribbean, South Asian, Chinese, or other Asian backgrounds, thresholds are reduced by 2.5 kg/m² to reflect higher metabolic risk at lower BMI

• Referral to and treatment within a tier 3 or tier 4 specialist weight management service

• Treatment is currently limited to a maximum of two years under NICE TA875

NHS availability of Wegovy remains limited due to ongoing supply constraints and the phased rollout of specialist services across England.

Liraglutide (Saxenda) has a separate NICE appraisal (TA664) with more specific eligibility criteria:

• BMI ≥35 kg/m² (or ethnicity-adjusted equivalent) with non-diabetic hyperglycaemia (pre-diabetes) and high cardiovascular risk

• Must be used within a specialist weight management service

• Similar ethnicity-adjusted BMI thresholds apply as for semaglutide

• A 12-week assessment at the 3 mg dose is recommended; treatment should be discontinued if the person has not lost at least 5% of their initial body weight

Naltrexone/bupropion (Mysimba) holds a UK marketing authorisation for weight management but is not routinely commissioned nationally on the NHS; availability varies by local integrated care system (ICS). Private prescribing is possible but requires careful clinical oversight given its contraindication profile.

Patients who do not meet NHS criteria may explore private prescribing routes. Your GP is the appropriate first point of contact to assess eligibility and discuss referral pathways.

Cost, Availability and Practical Differences in the UK

Injectable GLP-1 receptor agonists are considerably more expensive privately than orlistat, and NHS availability of Wegovy remains limited due to supply constraints and phased specialist service rollout.

The practical and financial differences between injections and pills are considerable and may significantly influence which option is suitable for an individual.

Cost on the NHS is not a direct concern for eligible patients, as prescriptions are subject to standard NHS charges (or are free for those with exemptions). Private costs differ substantially and vary by dose, provider, and current supply conditions — prices change frequently and any figures quoted online may quickly become outdated. As a general guide, injectable GLP-1 receptor agonists (Wegovy, Saxenda) are considerably more expensive per month than orlistat, which is available over the counter as Alli (60 mg) at relatively modest cost. Patients considering private treatment should obtain up-to-date pricing directly from a regulated provider.

Practical administration also differs meaningfully:

• Semaglutide (Wegovy) is administered once weekly by subcutaneous injection using a pre-filled pen device; most patients find this straightforward after initial training

• Liraglutide (Saxenda) requires daily subcutaneous injection

• Orlistat tablets are taken three times daily with meals containing fat; the dose should be skipped if a meal is fat-free or missed

• Naltrexone/bupropion (Mysimba) is taken orally with a gradual dose escalation over four weeks

Storage of injectable pens: Before first use, pens should be stored in a refrigerator (2–8°C). Once in use, pens may generally be kept at room temperature (below 30°C) for a defined period — this varies by product (refer to the specific SmPC or patient information leaflet for exact durations). Pens should not be frozen.

Availability has been a significant issue in the UK. The MHRA and NHS England have both acknowledged supply shortages of semaglutide products, with guidance issued to prioritise existing patients with type 2 diabetes (who use lower-dose Ozempic) over new weight management prescriptions. Patients and prescribers should check current NHS England supply guidance.

For those considering private treatment, it is essential to use a regulated UK prescriber — either a GMC-registered doctor or an NMC-registered prescribing nurse — and to obtain medicines only from a GPhC-registered pharmacy or CQC-regulated provider. Unlicensed, compounded, or counterfeit products sourced from unregulated online suppliers pose serious safety risks and should be avoided.

Choosing the Right Option With Your GP or Specialist

Your GP is the best starting point to assess BMI, comorbidities, contraindications, and NHS eligibility, as no single weight loss medication suits every individual.

There is no single 'best' weight loss medication that suits every individual. The right choice depends on a careful assessment of medical history, lifestyle, treatment goals, and personal preference — a conversation best had with a qualified healthcare professional.

Your GP is the ideal starting point. They can:

• Assess your BMI (including ethnicity-adjusted thresholds where relevant), comorbidities, and overall cardiovascular risk

• Review contraindications and clinically important drug interactions — for example, orlistat can reduce absorption of ciclosporin, affect INR in those taking warfarin, and requires careful timing with levothyroxine; GLP-1 receptor agonists may increase hypoglycaemia risk when used alongside insulin or sulfonylureas

• Determine whether you meet NHS eligibility criteria or require referral to a specialist weight management service

• Provide ongoing monitoring, including weight, blood pressure, blood glucose, and — where relevant — INR or thyroid function

For individuals with type 2 diabetes or established cardiovascular disease, injectable GLP-1 receptor agonists may offer additional clinical benefits beyond weight loss, including improved glycaemic control. Evidence from the SELECT trial also suggests cardiovascular risk reduction with semaglutide in people with overweight or obesity and established cardiovascular disease; however, cardiovascular risk reduction is not currently a licensed indication for Wegovy in the UK, and your GP or specialist will weigh the available evidence carefully in the context of your individual circumstances.

For those seeking a lower-cost, lower-intensity starting point, orlistat remains a clinically validated option, particularly when combined with structured dietary support. It may also be appropriate for individuals who are uncomfortable with self-injection. Naltrexone/bupropion (Mysimba) offers an alternative oral mechanism for those who are eligible and for whom local NHS commissioning or private prescribing is available.

Women planning a pregnancy should note that semaglutide should be stopped at least 2 months before conception; this should be discussed with a GP or specialist in advance.

It is important to approach weight management with realistic expectations. Medication is a tool — not a cure — and works best alongside sustainable dietary changes, increased physical activity, and behavioural support.

Seek urgent medical attention (call 999 or NHS 111) if you experience any of the following during treatment:

• Severe or persistent abdominal pain (possible pancreatitis)

• Signs of a severe allergic reaction (swelling of the face, lips, or throat; difficulty breathing)

• Jaundice, dark urine, or severe fatigue (possible hepatic injury, particularly with orlistat)

• Symptoms of severe dehydration (persistent vomiting, inability to keep fluids down)

Any suspected side effects should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Ultimately, the most effective option is the one you can safely tolerate, consistently adhere to, and use as part of a broader, long-term approach to health.

Frequently Asked Questions